Nvp-lde225
| Title | Journal |
|---|---|
| Sonidegib: First Global Approval. | Drugs 20150901 |
| Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers. | Cancer chemotherapy and pharmacology 20140701 |
| Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. | Nature medicine 20140701 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. | Bioorganic & medicinal chemistry 20121115 |
| Smoothened antagonists reverse taxane resistance in ovarian cancer. | Molecular cancer therapeutics 20120701 |
| Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. | Annals of surgery 20111101 |
| Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. | The Journal of investigative dermatology 20110801 |
| Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. | Cancer research 20110801 |
| Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. | ACS medicinal chemistry letters 20100610 |